This compound is primarily utilized in the development of PROTACs (Proteolysis Targeting Chimeras), which are innovative therapeutic molecules designed to target and degrade specific proteins within cells. It functions by binding to BET proteins, a family of proteins involved in regulating gene expression. By incorporating this moiety into a PROTAC, researchers can effectively degrade BET proteins, which are often implicated in various diseases, including cancer and inflammatory conditions. This approach offers a promising strategy for targeting undruggable proteins and overcoming resistance to traditional therapies. Its application is particularly relevant in preclinical research aimed at understanding disease mechanisms and developing novel treatments.